Cargando…

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), a member of the tumor necrosis factor receptor superfamily essential for osteoclastogenesis. Denosumab treatment is associated with a rapid, sustained, and reversible reduction in bone turno...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anastasilakis, Athanasios D, Toulis, Konstantinos A, Polyzos, Stergios A, Anastasilakis, Chrysostomos D, Makras, Polyzois
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387828/ https://www.ncbi.nlm.nih.gov/pubmed/22767993 http://dx.doi.org/10.2147/TCRM.S24239

Ejemplares similares

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
por: Anastasilakis, Athanasios D., et al.
Publicado: (2020)

Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass
por: Anastasilakis, Athanasios D., et al.
Publicado: (2019)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Adult Langerhans Cell Histiocytosis and the Skeleton
por: Georgakopoulou, Danae, et al.
Publicado: (2022)

Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021)

Bone metabolism in Langerhans cell histiocytosis
por: Anastasilakis, Athanasios D, et al.
Publicado: (2018)

Approach to the management of β thalassemia major associated osteoporosis - a long-standing relationship revisited
por: Yavropoulou, Maria P., et al.
Publicado: (2022)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

Gender Predilection in Sporadic Parathyroid Adenomas
por: Yavropoulou, Maria P., et al.
Publicado: (2020)

Lipid Profile after Pharmacologic Discontinuation and Restoration of Menstruation in Women with Endometriosis: A 12-Month Observational Prospective Study
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Obesity, osteoporosis and bone metabolism
por: Gkastaris, Konstantinos, et al.
Publicado: (2020)

Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium
por: Fahrleitner-Pammer, A., et al.
Publicado: (2017)

Zoledronic acid is effective in the management of migratory osteoporosis unresponsive to conservative treatment and risedronate: A case report
por: Evangelatos, Gerasimos, et al.
Publicado: (2021)

Circulating and Tissue Expression Profile of MicroRNAs in Primary Hyperparathyroidism Caused by Sporadic Parathyroid Adenomas
por: Yavropoulou, Maria P, et al.
Publicado: (2020)

Cost-effective osteoporosis treatment thresholds for people living with HIV infection in Greece
por: Makras, Polyzois, et al.
Publicado: (2017)

Long-term consequences of osteoporosis therapy with denosumab
por: Bandeira, Francisco, et al.
Publicado: (2022)

Parathyroid Disease in Pregnancy and Lactation: A Narrative Review of the Literature
por: Tsourdi, Elena, et al.
Publicado: (2021)

Short-term efficacy and safety of zoledronate acid or denosumab in Japanese patients with postmenopausal osteoporosis
por: Nakamura, Yumejiro, et al.
Publicado: (2021)

Efficacy of Anti-TNF Agents as Adjunctive Therapy for Knee Synovitis Refractory to Disease-Modifying Antirheumatic Drugs in Patients with Peripheral Spondyloarthritis
por: Sakellariou, Grigorios T., et al.
Publicado: (2013)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Efficacy of Denosumab for Osteoporosis in Patients with Rheumatic Diseases
por: Kaneko, Kaichi, et al.
Publicado: (2022)

The efficacy of denosumab in Korean male patients with osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis—Case Series
por: Kobayashi, Tsukasa, et al.
Publicado: (2018)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

P03 Long term denosumab treatment in osteoporosis - a case series
por: Premathilake, Nimanthi, et al.
Publicado: (2023)

Efficacy and Safety of 3‐Year Denosumab Therapy for Osteoporosis in Patients With Autoimmune Liver Diseases
por: Arase, Yoshitaka, et al.
Publicado: (2019)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Deferasirox: appraisal of safety and efficacy in long-term therapy
por: Chaudhary, Preeti, et al.
Publicado: (2013)

Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia® (denosumab) for the treatment of postmenopausal osteoporosis‡
por: Xue, Fei, et al.
Publicado: (2013)

Irisin and Bone in Sickness and in Health: A Narrative Review of the Literature
por: Tsourdi, Elena, et al.
Publicado: (2022)

Efficacy of Denosumab for Osteoporosis in Two Patients with Adult-Onset Still’s Disease—Denosumab Efficacy in Osteoporotic Still’s Disease Patients
por: Kumaki, Daiki, et al.
Publicado: (2018)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2018)

Response to letter to the Editors—Safety of long-term denosumab therapy
por: Stopeck, Alison T., et al.
Publicado: (2016)

GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
por: Hadji, P., et al.
Publicado: (2016)

Disease Burden and Treatment Preferences Amongst Postmenopausal Women with Severe Osteoporosis in Greece
por: Souliotis, Kyriakos, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1aleo75p5pcmbrujn751ni5e5c